This was in line with the study by Manzano et al. that also reported an increased caspase-3, -7, -8 and -9 activity in platelets of both TPO-RA treated and NR-ITP patients [54], indicating that unlike for IVIg, the TPO-RA response cannot be monitored or predicted through analysis of platelet apoptosis. The gene discussed is CASP3; the disease is rheumatoid arthritis.